Maury Raycroft
Stock Analyst at Jefferies
(1.43)
# 3,576
Out of 5,124 analysts
57
Total ratings
34.88%
Success rate
-8.34%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $114 → $63 | $22.54 | +179.50% | 1 | Dec 30, 2025 | |
| MREO Mereo BioPharma Group | Downgrades: Hold | $7 → $0.5 | $0.38 | +31.93% | 2 | Dec 30, 2025 | |
| CELC Celcuity | Maintains: Buy | $108 → $134 | $105.02 | +27.59% | 2 | Dec 2, 2025 | |
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $15.44 | +36.01% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.32 | +21.21% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $406.40 | +35.09% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.25 | +12.00% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $25.05 | -40.12% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.97 | +17.85% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $8.05 | +558.39% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $4.91 | +62.93% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.44 | +575.52% | 1 | Dec 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $3.63 | +65.29% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $9.67 | +96.48% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $3.70 | +305.41% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $36.20 | +7.73% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.37 | +1,534.43% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.74 | +1,221.84% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $2.82 | +6,814.89% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.58 | +45.12% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $46.52 | -87.10% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $70.81 | +5.92% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $1.91 | +475.92% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $26.40 | +2.27% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.50 | +233.33% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.75 | +269.23% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.49 | +1,812.57% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $58.19 | +195.58% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.60 | +1,707.69% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $9.73 | +331.65% | 3 | Nov 1, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Buy
Price Target: $114 → $63
Current: $22.54
Upside: +179.50%
Mereo BioPharma Group
Dec 30, 2025
Downgrades: Hold
Price Target: $7 → $0.5
Current: $0.38
Upside: +31.93%
Celcuity
Dec 2, 2025
Maintains: Buy
Price Target: $108 → $134
Current: $105.02
Upside: +27.59%
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $15.44
Upside: +36.01%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.32
Upside: +21.21%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $406.40
Upside: +35.09%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.25
Upside: +12.00%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $25.05
Upside: -40.12%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.97
Upside: +17.85%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $8.05
Upside: +558.39%
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.91
Upside: +62.93%
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.44
Upside: +575.52%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $3.63
Upside: +65.29%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $9.67
Upside: +96.48%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.70
Upside: +305.41%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $36.20
Upside: +7.73%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.37
Upside: +1,534.43%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.74
Upside: +1,221.84%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $2.82
Upside: +6,814.89%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.58
Upside: +45.12%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $46.52
Upside: -87.10%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $70.81
Upside: +5.92%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $1.91
Upside: +475.92%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $26.40
Upside: +2.27%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.50
Upside: +233.33%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $9.75
Upside: +269.23%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.49
Upside: +1,812.57%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $58.19
Upside: +195.58%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.60
Upside: +1,707.69%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $9.73
Upside: +331.65%